Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1348342 | 0.87 | TP53 (0.51) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL6030715 | 0.87 | KDM4E (0.60) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL1348580 | 0.86 | TP53 (0.64) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL14827419 | 0.86 | FUBP1 (0.56) | MAPTTP53HPGDRAD51KDM4E | |
| SCHEMBL6031855 | 0.85 | TP53 (0.52) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL31560196 | 0.85 | TP53 (0.68) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL31560193 | 0.82 | TP53 (0.47) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL6031420 | 0.82 | HPGD (0.67) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL6031252 | 0.81 | TP53 (0.45) | MAPTTP53HPGDKDM4EALDH1A1 | |
| SCHEMBL1349337 | 0.81 | TTR (0.60) | MAPTTP53HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899187-A | Synthesis method of pyrazolo [1,5-a ] pyrimidine-7-amine compound | 湖南九典制药股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-7098335-B2 | Pyrazolopyrimidine compositions | ICAGEN, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050215569-A1 | Pyrazolopyrimidines | ICAGEN, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| US-6833371-B2 | Contacting cell with a sodium channel-inhibiting amount of a compound comprising a pyrazolopyrimidine moiety for decreasing ion flow through a voltage-dependent sodium channel in a cell | ICAGEN, INC. | 2004-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215569-A1 | Pyrazolopyrimidines | SCN3A, TRPV3, P2RX3 | MAPT 3256/4885TP53 4683/4885HPGD 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.